Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?-Reference-Cited by-同舟云学术

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?

Published:2023-09-01 Issue:11 Volume:12 Page:
ISSN:2049-3614
Container-title:Endocrine Connections
language:
Short-container-title:

Author:

Lisco Giuseppe¹^ORCID,De Tullio Anna¹,Disoteo Olga²,Piazzolla Giuseppina¹,Guastamacchia Edoardo¹,Sabbà Carlo¹,De Geronimo Vincenzo³,Papini Enrico⁴,Triggiani Vincenzo¹

Affiliation:

1. Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy

2. Diabetology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

3. Unit of Endocrinology, Policlinico Morgagni CCD, Catania, Italy

4. Department of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.

Publisher

Bioscientifica

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://ec.bioscientifica.com/downloadpdf/journals/ec/12/11/EC-23-0257.xml

Reference63 articles.

1. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis;Sabouret,2023

2. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: a rapid review of randomized controlled trials and meta-analysis;Lisco,2022

3. Once-weekly semaglutide induces an early improvement in body composition in patients with Type 2 diabetes: a 26-week prospective real-life study;Volpe,2022

4. Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study;Volpe,2022

5. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice;Wharton,2022